Answers are grounded in this paper and cite their sources.
Aim: This review aims to assist physicians and payers in assessing the efficacy and safety of bevacizumab in real-world clinical practice by identifying evidence on the comparative effectiveness and safety of bevacizumab in its most frequent indications. Materials & methods: In a systematic review of the published literature, electronic databases (Embase®, MEDLINE® and the Cochrane Library) were searched in May 2016 and updated in January 2017; 20 scientific congresses were searched in 2014–2017. Results: Of 61 included publications, 49, eight, four and 0 concerned metastatic colorectal cancer, metastatic breast cancer, advanced ovarian cancer and cervical cancer, respectively. Fifteen publications (metastatic colorectal cancer) reported on factors predictive of response to therapy. Conclusion: Effectiveness findings from real-world studies broadly supported results from registration studies.
No takes yet. Share an insight, caveat, or question.
Raouf et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: